CN101391076A - Huidouba extract traditional Chinese medicine preparation for treating diabetes - Google Patents
Huidouba extract traditional Chinese medicine preparation for treating diabetes Download PDFInfo
- Publication number
- CN101391076A CN101391076A CNA2008100509162A CN200810050916A CN101391076A CN 101391076 A CN101391076 A CN 101391076A CN A2008100509162 A CNA2008100509162 A CN A2008100509162A CN 200810050916 A CN200810050916 A CN 200810050916A CN 101391076 A CN101391076 A CN 101391076A
- Authority
- CN
- China
- Prior art keywords
- extract
- group
- chinese medicine
- present
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a huidouba extract traditional Chinese medicine complex preparation for treating diabetes mellitus, which is prepared by the uniform mixing of red spider nest extract, ginkgo biloba leave extract, aloe extract and turmeric extract according to a proportion; and the huidouba is the nest spun by red spiders in Mt. Emei of Sichuan province. The invention is an extract of pure traditional Chinese herbs to be prepared into the preparation, is used for treating and preventing diabetes mellitus, has the advantages of rapid disappearance of clinical symptoms and small toxic and side effects, cures the causes and symptoms, and is effective in treatment.
Description
Technical field:
The present invention relates to the drug regimen that Heidouba extract is a main component, disclose medicine composite preparation in a kind of Heidouba extract for the treatment of diabetes, belong to technical field of Chinese medicines.
Background technology:
Gray Root Pakistan is that a kind of red spider of special product weaves silk and makes nest below the Camellia sinensis.This medical material is peculiar by the Mount Emei, is that the Aranea of being tied on the Camellia sinensis of Mount Emei's height above sea level more than 1200 meters is that raw material is made.The Xinjiang region produced in small quantities, relatively the Gray Root Pakistan quality soil of Mount Emei is quite a lot of, the regional sources of goods such as nine stockaded village's Abas all derive from the Mount Emei, Gray Root Pakistan is Mount Emei's disease medicine of passing on from generation to generation among the people over thousand, but in use is with its former medicine, and its mechanism of curing the disease is also indeterminate, therefore, has influenced it and has promoted the use of the effect of curing the sickness to save the patient.
Summary of the invention:
The present invention discloses a kind of Chinese medicine preparation of the present invention for the treatment of diabetes, is used to the non-insulin-dependent diabetes mellitus and the treatment non-insulin-dependent diabetes mellitus that prevent alloxan to cause.
The invention also discloses the preparation technology of medicine composite preparation in this, be applicable to suitability for industrialized production.
The present invention further discloses the purposes of Heidouba extract in preparation treatment diabetes medicament.
The present invention treats the Chinese medicine preparation of the present invention of diabetes, by following raw materials by weight portion than making:
40～80 parts of Heidouba extracts, 45～60 parts of Folium Ginkgo extract, 20～40 parts of Aloe extracts, 15～30 parts of Rhizoma Curcumae Longae extracts.
The optimum ratio of medicine composite preparation is among the present invention:
50 parts of Heidouba extracts, 40 parts of Folium Ginkgo extract, 25 parts of Aloe extracts, 15 parts of Rhizoma Curcumae Longae extracts.
The preparation technology of medicine composite preparation is as follows among the present invention:
According to the above ratio Heidouba extract, Folium Ginkgo extract, Aloe extract, Rhizoma Curcumae Longae extract mix homogeneously are got final product.
Usage and dosage: oral; 3 times/day; 5～8g/ time;
Extract refers to the concentrated prepared product of the Main Ingredients and Appearance of medicinal plants.Usually, extract can cut or grind exsiccant material then by dry.Then can be at the solvent of suitable selection, normally in ethanol/water mixture, methanol, butanols, isobutanol, acetone, ethane, petroleum ether or other organic solvent, leaching process is carried out in (temperature/pressure) extraction by means of immersion, diafiltration, diafiltration again, reflux, extract,, super extraction or CO 2 supercritical, extract can evaporate then and concentrate, and obtains soft extract flow extractum and/or final exsiccant extract, dry extract by spray drying, vacuum drying oven drying, fluid bed drying or lyophilizing.
Gray Root Pakistan has replenishing QI to invigorate the spleen, nourishing kidney yin, Yin Yang balancing, and QI and blood regulating, correcting the metabolism random effect of wadding a quilt with cotton is monarch drug; Folium Ginkgo is sweet, bitter in the mouth, puckery, flat.GUIXIN, lung meridian.Have and astringe the lung, relieving asthma, activating blood circulation to dissipate blood stasis, analgesic function.Be used for cough and asthma due to lung deficiency; Mainly contain flavone compound, ginkgolide compound in the Folium Ginkgo extract, to blood circulation, particularly cardio-cerebrovascular is had protective effect, can remove free radical, suppress cell senescence, the liver protecting, renal function are ministerial drug; Aloe has is good for the stomach, and bowel relieving detoxifcation, eliminates constipation, eliminates the effect of scorching swollen, antibiotic, defying age, strong health.Rhizoma Curcumae Longae has the effect of removing blood stasis circulation of qi promoting, inducing menstruation to relieve menalgia,
The Chinese medicine preparation that is used to prevent and treats diabetes disclosed by the invention is the excipient by this extract and the 70-40% of 40-70%.
In order to prepare the solution that is suitable for the outer administration of gastrointestinal tract, can use distilled water, water for injection, isotonic sodium chlorrde solution or glucose solution, perhaps low solution (for example 1-100mM) phosphate buffered saline (PBS) (PBS) is as carrier or excipient.Can in the preparation of these gastrointestinal tract external administrations, add one or more other auxiliary elements or additives, for example can use ascorbic acid as antioxidant, use sodium benzoate or methyl hydroxybenzoate as antiseptic, use dimethyl sulfoxide as absorption enhancer.
In order to prepare tablet, powder agent, suspending agent or the capsule that is suitable for oral administration, can use sucrose, galactose, corn starch, gelatin, lipid, microcrystalline Cellulose, Pulvis Talci etc. as carrier or excipient.Be suitable in the preparation of oral administration at these, also can contain other proper additive, for example solubilizing agent, disintegrating agent, lubricant, absorption enhancer, antiseptic, correctives, diluent, adsorbent, excipient, dispersant, surfactant, coloring agent etc.
Preferably pharmaceutical composition of the present invention being made route of administration is the injection that intravenous or intramuscular injection are suitable for these route of administration, for example injection, lyophilized injectable powder etc.The dosage of intravenous administration is generally 10-200mg every day.Another preferred route of administering of pharmaceutical composition of the present invention is the various dosage forms that are suitable for oral administration, for example tablet, powder agent, capsule, oral liquid or Emulsion, and the unit dose of these oral formulations generally comprises this extract of 10-1000mg.
Following experiment has shown the pharmaceutical preparation of the present invention pharmacological action of (comprising compound formulation and Heidouba extract preparation)
Experimental example 1
Chinese medicine preparation of the present invention is to the influence of experimental diabetic rats blood glucose
Observe the hypoglycemic activity that chain urase element is caused diabetes rat with Chinese medicine preparation of the present invention.
1. experiment material and method
1.1 experiment material:
Laboratory animal, the Wistar in 6 ages in week is male rat body weight 180 ± 20g, available from Jilin University's medical board Experimental Animal Center, in 23 ± 1 ℃ of room temperatures, humidity 55 ± 10%, rate of ventilation 20 ± 2 times/time, the light and shade cycling conditions were raised for 1 week down in 12 hours, for experiment.Between the preparation feeding period, feeding solid feed (available from Jilin University's medical board Experimental Animal Center), water freely absorbs.Medicine composite preparation prepares voluntarily among the present invention.
1.2 experimental technique:
1.2.1 hyperglycemia model is made in grouping: select 50 of qualified rats, be divided into 5 groups: 1 group is the normal control group, 2 groups-5 groups in preceding 3 days of experiment beginning, tail vein injection streptozotocin 65mg/kg, choose the rat that blood glucose is higher than 11.0mmol/L and divide into groups, the 2nd group is STZ transaction module group, equivalent pure water (0.5ml/ time, early 8 o'clock, in 12 o'clock, late 16 o'clock, totally 3 times) force per os to give.
1.2.2 administration: 3rd, force per os to give Chinese medicine preparation of the present invention respectively for 4,5 groups: the 3rd group is Heidouba extract C group of the present invention (80mg/ml) (0.5ml/ time for medicine composite preparation A group (80mg/ml) among the present invention, the 4th group for medicine composite preparation B group (160mg/ml) among the present invention, the 5th group, early 8 o'clock, in 12 o'clock, late 16 o'clock, totally 3 times), continuous 14 days.After administration, measured the blood glucose amount in 0 day, 7 days, 14 days respectively.Experimental session feedstuff and water freely absorb.
1.2.3 blood sugar detection: water is can't help in 16h before each measuring blood when 18:00 (be evening the previous day) rat fasting, at 10:00 in the morning, under the no anesthesia, takes a blood sample from rat tail vein, measures the blood sugar concentration in its blood.Glucose in the blood plasma is measured with Beijing northization safe clinical reagent company limited production glucose kit-GLU (oxidation enzyme process).
2. statistical disposition
Data represent that with mean+SD poor intentionally (significant difference) between many groups compares meansigma methods with Super ANOVA soft according to the Dunnett method.P＜0.05 is judged to be significant difference on the statistics.
3. result: as shown in table 1, rat tail vein injection streptozotocin is after 3 days, and its blood sugar concentration is apparently higher than the normal control group.Behind the successive administration 7 days, 14 days, Chinese medicine preparation A group of the present invention, Chinese medicine preparation B of the present invention group, Chinese medicine preparation C of the present invention group blood glucose all are starkly lower than model group.
Table 1 Chinese medicine preparation of the present invention is to the influence of rat blood sugar
N=5, * p＜0.05vs model group
4. conclusion: experiment adopts streptozotocin to prepare the rat diabetes model, streptozotocin can be optionally by islets of langerhans β-cellular uptake, cause β-necrocytosis, thus performance and human akin diabetic symptom: hyperglycemia, glucose in urine, polyuria, polyphagia, weight loss, hyperlipemia, beta-oxybutyria and acidosis.Experimental results show that Chinese medicine preparation of the present invention has blood sugar reducing function.
Experimental example 2
Chinese medicine preparation of the present invention is to the influence of tissue of experimental diabetic mice blood glucose
With Chinese medicine preparation of the present invention, observe the hypoglycemic activity that alloxan is caused diabetic mice.
1. experiment material and method
1.1 experiment material: laboratory animal, adopt male kunming mouse in 4 ages in week, body weight 20 ± 2g, available from Jilin University's medical board Experimental Animal Center, raise under the environment of alternate cycles on 12h daytime/night 23 ± 1 ℃ of temperature, humidity 55 ± 10%, rate of ventilation 20 ± 2 times/time, the pellet of feeding standard is freely ingested and water.Chinese medicine preparation of the present invention is provided by this chamber.
1.2 experimental technique:
1.2.1 hyperglycemia model is made in grouping: select 80 of qualified mices, be divided into 5 groups: 1 group is the normal control group, 2 groups-5 groups in preceding 3 days of experiment beginning, lumbar injection alloxan 150mg/kg, choosing the mice that blood glucose is higher than 11.0mmol/L divides into groups, the 2nd group is alloxan transaction module group, and equivalent pure water (0.2ml/ time, sky) forces per os to give.
1.2.2 administration: 3rd, force to irritate stomach respectively and give Chinese medicine preparation of the present invention for 4,5 groups, the 3rd group is Heidouba extract C group of the present invention (80mg/ml) for medicine composite preparation A group (80mg/ml) among the present invention, the 4th group for medicine composite preparation B group (160mg/ml) among the present invention, the 5th group, irritating the stomach amount is 0.2ml/ time, sky, continuous 14 days.After administration 0 day, the 7th day and measured the amount of blood glucose on the 14th day respectively.Experimental session feedstuff and water freely absorb.
1.2.3 blood sugar detection: 16h before measuring, water is can't help in the mice fasting, under no anesthesia, from the blood sampling of mouse orbit venous plexus, measures the blood sugar concentration in its blood.Glucose in the blood plasma is measured with Beijing northization safe clinical reagent company limited production glucose kit-GLU (oxidase).
2 statistical dispositions
Data represent that with mean+SD poor intentionally (significant differences) set up compare meansigma methods with Supcr ANOVA soft according to the Dunnett method more.P＜0.05 is judged to be significant difference on the statistics.
3 results: as shown in table 2, mouse peritoneal injection alloxan is after 3 days, and its blood sugar concentration is apparently higher than the normal control group.Behind the successive administration 7 days, 14 days, Chinese medicine preparation administration group blood glucose of the present invention all is starkly lower than model group.
Table 2 Chinese medicine preparation of the present invention is to the influence of mouse blood sugar
N=5, * p＜0.05vs model group
4 conclusions: experiment adopts alloxan to prepare the mice diabetes model, alloxan can optionally be absorbed by the pancreas beta cell, cause the beta cell necrosis, thus performance and human akin diabetic symptom: hyperglycemia, glucose in urine, polyuria, polyphagia, weight loss, hyperlipemia, beta-oxybutyria and acidosis.Originally experimental results show that Chinese medicine preparation of the present invention has hypoglycemic activity.
Experimental example 3
Chinese medicine preparation of the present invention is to the observation of rat prevention artificial diabetes effect
With Chinese medicine preparation of the present invention, observe its influence to the effect of rat prevention artificial diabetes.
1. experiment material and method
1.1 experiment material:
Laboratory animal, the Wistar in 6 ages in week is male rat body weight 180 ± 20g, available from Jilin University's medical board Experimental Animal Center, in 23 ± 1 ℃ of room temperatures, humidity 55 ± 10%, rate of ventilation 20 ± 2 times/time, the light and shade cycling conditions were raised for 1 week down in 12 hours, for experiment.Between the preparation feeding period, feeding solid feed (available from Jilin University's medical board Experimental Animal Center), water freely absorbs.Chinese medicine preparation of the present invention is prepared voluntarily by this chamber.
1.2 experimental technique:
1.2.1 medicine is prepared and is used: select 50 of qualified rats, be divided into 5 groups, every group 10, promptly the 1st group is that to be model control group, the 3rd group be Heidouba extract formulation C group of the present invention (80mg/ml) for medicine composite preparation B group (160mg/ml) among the present invention, the 5th group for medicine composite preparation A group (80mg/ml) among the present invention, the 4th group for blank group, the 2nd group.Model control group force to be irritated stomach and is given normal saline (0.5ml/ time, early, evening totally 2 times), and the administration group is forced to irritate stomach respectively and given Chinese medicine preparation of the present invention (0.5ml/ time, early, evening totally 2 times), continuous 14 days.Experimental session feedstuff and water freely absorb.
1.2.2 blood sugar detection: carried out at the 15th day.Water is can't help in 16h before measuring blood when 18:00 (be evening the previous day) rat fasting, at 10:00 in the morning, under the no anesthesia, takes a blood sample from rat tail vein, measures the blood sugar concentration in its blood.2-5 groups are at tail vein injection streptozotocin 65mg/kg then.Survey blood glucose (water is can't help in the 16h fasting before surveying) behind the 72h, under no anesthesia, tail vein blood, centrifugal separation plasma immediately.Glucose in the blood plasma is measured with Beijing northization safe clinical reagent company limited production glucose kit-GLU (oxidase).
2. statistical analysis
Data represent that with meansigma methods ± standard error the difference employing t-check between matched group and processed group and on the statistics between the processing front and back adopts ANOVA to add up P＜0.05 for repeated measure, thinks remarkable on the statistics.
3. result: Chinese medicine preparation of the present invention is to the observation of rat prevention artificial diabetes effect, and experimental group and control rats blood glucose before the intravenous injection streptozotocin all is in normal level.Behind the intravenous injection STZ, blank is formed the mould rate far above 3 Chinese medicine preparation administration matched groups of the present invention.Behind the successive administration 14 days, effect obviously improves Chinese medicine preparation of the present invention to the rat experiment diabetes mellitus prevention.
Table 3 Chinese medicine preparation of the present invention is to the influence of the rat diabetes that caused by streptozotocin
N=5, * p＜0.05vs model group
4. conclusion
This paper result of study shows: Chinese medicine preparation of the present invention can increase the preventive effect of rat to artificial diabetes.
Experimental example 4
Chinese medicine preparation of the present invention is to the observation of mice prevention artificial diabetes effect
Observe its influence with Chinese medicine preparation of the present invention to the effect of mice prevention artificial diabetes.
1. experiment material and method
1.1 experiment material: laboratory animal, employing male mouse of kunming in 4 age in week, body weight 20 ± 2g, available from Jilin University's medical board Experimental Animal Center, raise under the environment of alternate cycles on 12h daytime/night 23 ± 1 ℃ of temperature, humidity 55 ± 10%, rate of ventilation 20 ± 2 times/time, the pellet of feeding standard is freely ingested and water.Chinese medicine preparation of the present invention is provided by this chamber.
1.2 experimental technique:
1.2.1 medicine is prepared and used: select 50 of qualified mices, be divided into 5 groups: the 1st group is that to be model control group, the 3rd group be Heidouba extract formulation C group of the present invention (80mg/ml) for medicine composite preparation B group (160mg/ml) among the present invention, the 5th group for medicine composite preparation A group (80mg/ml) among the present invention, the 4th group for blank group, the 2nd group.The blank group force to be irritated stomach and is given normal saline (0.5ml/ time, early, evening totally 2 times), and the administration group is forced to irritate stomach respectively and given Chinese medicine preparation of the present invention (0.5ml/ time, early, evening totally 2 times), continuous 14 days.Experimental session feedstuff and water freely absorb.
1.2.2 blood sugar detection: carried out at the 15th day.Fasting be can't help water 12 hours, measured blood sugar concentration.Under no anesthesia,, measure the blood sugar concentration in its blood from the blood sampling of mouse orbit venous plexus.Pneumoretroperitoneum injection alloxan 150mg/kg.72h (survey before 12h fasting can't help water) venous blood collection under no anesthesia, centrifugal separation plasma immediately, the glucose in the blood plasma is with Beijing northization safe clinical reagent company limited production glucose kit-GLU (oxidase) mensuration.
2. statistical disposition
Data represent that with mean+SD poor intentionally (significant differences) set up compare meansigma methods with Super ANOVA soft according to the Dunnett method more.P＜0.05 is judged to be significant difference on the statistics.
3. result: Chinese medicine preparation of the present invention all is in normal level to observation experiment group and control mice blood glucose before the lumbar injection alloxan of the effect of mice prevention artificial diabetes.Behind the lumbar injection alloxan, blank is formed the mould rate far above 3 Chinese medicine preparation administration matched groups of the present invention.Behind the successive administration 14 days, effect obviously improves Chinese medicine preparation administration group of the present invention to the mouse experiment diabetes mellitus prevention.
Table 4 Chinese medicine preparation of the present invention is to the influence of the mice diabetes that caused by alloxan
N=5, * p＜0.05vs model group
4. conclusion
Result of study of the present invention shows: Chinese medicine preparation of the present invention can increase the preventive effect of mice to artificial diabetes.
Experimental example 5
Chinese medicine preparation of the present invention to the rat glucose load after the blood glucose inhibiting observation of rising
With Chinese medicine preparation of the present invention observe its to the rat glucose load after the blood glucose inhibiting influence of rising.
1. experiment material and method
1.1 experiment material:
Laboratory animal, the Wistar in 6 ages in week is male rat body weight 180 ± 20g, available from Jilin University's medical board Experimental Animal Center, in 23 ± 1 ℃ of room temperatures, humidity 55 ± 10%, rate of ventilation 20 ± 2 times/time, 12h light and shade cycling condition was raised for 1 week down, for experiment.Between the preparation feeding period, feeding solid feed (available from Jilin University's medical board Experimental Animal Center), water freely absorbs.This chamber of Chinese medicine preparation of the present invention prepares voluntarily.
2. experimental technique:
2.1 hyperglycemia model is made in grouping: select 30 of qualified rats, be divided into 5 groups: 1 group is the normal control group, equivalent pure water (0.5ml/ time, 1 time/day); The 2nd group is the glyburide group, forces per os to give.
2.2 administration: 3rd, force the go on a hunger strike rat Chinese medicine preparation of the present invention of 12h of per os respectively for 4,5 groups, the 3rd group is Heidouba extract Chinese medicine preparation C group of the present invention (80mg/ml), dosage 0.5ml/ time for medicine composite preparation A group (80mg/ml) among the present invention, the 4th group for medicine composite preparation B group (160mg/ml) among the present invention, the 5th group.Behind the Give medicine 1h, the rat eye socket is got blood, gets behind the blood per os and forces to give glucose solution (loading of glucose is the 2.5g/kg body weight).Measure to the blood glucose before the glucose solution and blood glucose value after giving glucose solution 30min, 60min, 120min.Under no anesthesia, eye socket blood sampling, centrifugal separation plasma immediately.Glucose in the blood plasma is measured with Beijing northization safe clinical reagent company limited production glucose kit-GLU (oxidase).
3. statistical analysis
Data represent that with meansigma methods ± standard error the difference employing t-check between matched group and processed group and on the statistics between the processing front and back adopts ANOVA to add up P＜0.05 for repeated measure, thinks remarkable on the statistics.4. result: from table 5 experimental result, Chinese medicine preparation of the present invention has the obvious suppression effect to the blood sugar level in the diabetes rat blood, table 5 shown short-term in the time Chinese medicine preparation of the present invention to the influence of rat blood sugar level.After giving rat glucose (2.5g/kg body weight) 0min, 30min, 60min, 120min, the recruitment of blood glucose is compared with matched group in the rat blood, is starkly lower than the blood glucose recruitment of matched group, suppresses blood glucose effectively and rises.
Table 5 Chinese medicine preparation of the present invention is to the recruitment influence of rat blood sugar
N=5, * p＜0.05vs matched group
5. conclusion: result of study, after the normal rat glucose load, blood glucose rises, and has increased blood sugar concentration, Chinese medicine preparation administration group of the present invention, blood glucose rises and has obtained inhibition.
Experiments such as observation by to the influence of experimental diabetic rats, mouse blood sugar and rat, the effect of mice prevention artificial diabetes can draw, and Chinese medicine preparation of the present invention is to treatment and prevent diabetes determined curative effect.
Good effect of the present invention is: for pure Chinese herbal medicine extract, make preparation, be used for the treatment of and prevent diabetes, clinical symptom disappearance is rapid, and toxic and side effects is little, and treating both the principal and secondary aspects of a disease is evident in efficacy.
The specific embodiment:
Embodiment 1
With 70% soak with ethanol 24h of 15 times of weight of Gray Root Pakistan adding, 100 ℃ of continuous stirring are extracted 4 times, each 3h, merge extractive liquid.Extracting liquid filtering gets filtrate, and concentrating under reduced pressure gets Heidouba extract after the concentrated solution drying.
Embodiment 2
60% petroleum ether that Gray Root Pakistan is added 10 times of weight soaks 18h, and 100 ℃ of continuous stirring are extracted 4 times, each 3h, merge extractive liquid.Extracting liquid filtering gets filtrate, and concentrating under reduced pressure gets Heidouba extract after the concentrated solution drying.
Embodiment 3
16h is steeped in the water logging that Gray Root Pakistan is added 8 times of weight, and 100 ℃ of continuous stirring are extracted 4 times, each 3h, merge extractive liquid.Extracting liquid filtering gets filtrate, and concentrating under reduced pressure gets Heidouba extract after the concentrated solution drying.
Embodiment 4
Heidouba extract 70kg, Folium Ginkgo extract 60kg, Aloe extract 40kg, Rhizoma Curcumae Longae extract 30kg make concentrated granule according to the pharmaceutical technology of routine, 10g/ bag, sundry item should meet 2005 editions granule projects of Pharmacopoeia of People's Republic of China relevant requirements.
Embodiment 5
Heidouba extract 80kg, the Folium Ginkgo extract 50kg, Aloe extract 20kg, the Rhizoma Curcumae Longae extract 15kg that get embodiment 1 or 2 add excipient dextrin 60kg, mix homogeneously, the pelletize tabletting, make tablet, every 0.5g, sundry item should meet 2005 editions tablet projects of Pharmacopoeia of People's Republic of China relevant requirements.
Embodiment 6
Get Heidouba extract 40kg, Folium Ginkgo extract 45kg, Aloe extract 30kg, the Rhizoma Curcumae Longae extract 25kg part mix homogeneously of embodiment 3, pharmaceutical technology according to routine is made capsule, every 0.5g, sundry item should meet 2005 editions capsule projects of Pharmacopoeia of People's Republic of China relevant requirements.
Claims (4)
1, medicine composite preparation in a kind of Heidouba extract for the treatment of diabetes, by following raw materials by weight portion than making:
40～80 parts of Heidouba extracts, 45～60 parts of Folium Ginkgo extract, 20～40 parts of Aloe extracts, 15～30 parts of Rhizoma Curcumae Longae extracts.
2, medicine composite preparation in according to claim 1 is characterized in that by following raw materials by weight portion than making:
50 parts of Heidouba extracts, 40 parts of Folium Ginkgo extract, 25 parts of Aloe extracts, 15 parts of Rhizoma Curcumae Longae extracts.
3, middle medicine composite preparation according to claim 1 and 2, its preparation technology is as follows:
In proportion Heidouba extract, Folium Ginkgo extract, Aloe extract, Rhizoma Curcumae Longae extract mix homogeneously are got final product.
4, the purposes of Heidouba extract in preparation treatment diabetes medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100509162A CN101391076A (en) | 2008-07-04 | 2008-07-04 | Huidouba extract traditional Chinese medicine preparation for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100509162A CN101391076A (en) | 2008-07-04 | 2008-07-04 | Huidouba extract traditional Chinese medicine preparation for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101391076A true CN101391076A (en) | 2009-03-25 |
Family
ID=40491717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100509162A Pending CN101391076A (en) | 2008-07-04 | 2008-07-04 | Huidouba extract traditional Chinese medicine preparation for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101391076A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104825816A (en) * | 2015-05-14 | 2015-08-12 | 卢祥平 | Medicine for treating fatty liver, prostatitis, diabetes, nephralgia and kidney deficiency |
| CN105770710A (en) * | 2014-12-15 | 2016-07-20 | 张培祥 | Natural composition capable of preventing and treating new-onset diabetes mellitus caused by statin lipid-lowering medicines |
-
2008
- 2008-07-04 CN CNA2008100509162A patent/CN101391076A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770710A (en) * | 2014-12-15 | 2016-07-20 | 张培祥 | Natural composition capable of preventing and treating new-onset diabetes mellitus caused by statin lipid-lowering medicines |
| CN104825816A (en) * | 2015-05-14 | 2015-08-12 | 卢祥平 | Medicine for treating fatty liver, prostatitis, diabetes, nephralgia and kidney deficiency |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285231A (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN103446385A (en) | Traditional Chinese medicine preparation for treating diabetic complications | |
| CN101119740B (en) | Use of radix sanguisorbae and its extract for preparing medicament to increase RBC and hemoglobin | |
| CN104666373A (en) | Novel use of Eurycoma longifolia Jack | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| WO2009149585A1 (en) | Compositions for reducing blood glucose level and uses thereof | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN101167863B (en) | Proprietary Chinese medicine for treating diabetes and nephrosis and preparing method thereof | |
| CN1329049C (en) | Blood sugar- and blood pressure-lowering medicine | |
| CN100512796C (en) | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method | |
| CN102716135B (en) | Lupenone prevents in preparation or treats the application in the product of diabetes | |
| CN104352624A (en) | Application of Mongolian medicine Cymbaria n-butanol extract in preparation of medicine for preventing and curing diabetes | |
| CN104069344A (en) | Traditional Chinese medicine composition for treating cancer and preparation and preparation method thereof | |
| CN101391076A (en) | Huidouba extract traditional Chinese medicine preparation for treating diabetes | |
| CN107890528B (en) | Traditional Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| CN103463217B (en) | A kind of treat enteritis and dysentery extract, containing its preparation and its preparation method and application | |
| CN1686424B (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN1788758A (en) | Use of traditional Chinese medicine garden burnet and its extract in preparing drug for raising red cell and blood hemoglobin | |
| CN111700927B (en) | Medicinal and edible composition with blood sugar reducing effect and preparation method and application thereof | |
| CN100455300C (en) | Compound wild kiwi tablet and its preparing method | |
| CN101450162A (en) | Traditional Chinese medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN105327115A (en) | Phellinus linteus catharsis formula for prevention and cure of type II diabetes and preparation process thereof | |
| CN1977888B (en) | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza | |
| CN110420264B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN103285110B (en) | Traditional Chinese medicine for treating hyperlipidemia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090325 |